Which has higher earnings and valuation, GNS or IGG?

IG Group has higher revenue and earnings than Genus. IG Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.17 £7.87M £71.00 30.90 IG Group £949.10M 5.08 £533.35M £105.10 13.89

Is GNS or IGG more profitable?

IG Group has a net margin of 43.07% compared to Genus' net margin of 7.07%. IG Group's return on equity of 26.63% beat Genus' return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% IG Group 43.07% 26.63% 10.37%

Do analysts prefer GNS or DPH?

Genus presently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 46.61%. Given Genus' stronger consensus rating and higher probable upside, research analysts clearly believe Genus is more favorable than Dechra Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Dechra Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, HWDN or GNS?

Howden Joinery Group has higher revenue and earnings than Genus. Howden Joinery Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Howden Joinery Group £2.45B 1.77 £253.42M £49.00 16.09 Genus £672M 2.17 £7.87M £71.00 30.90

Do analysts recommend GNS or CTY?

Genus currently has a consensus target price of GBX 3,216.67, indicating a potential upside of 46.61%. Given Genus' stronger consensus rating and higher possible upside, equities analysts clearly believe Genus is more favorable than City of London. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 City of London 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, GNS or CTY?

City of London has lower revenue, but higher earnings than Genus. City of London is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.17 £7.87M £71.00 30.90 City of London £568.96M 5.37 £294.08M £113.99 5.20

Is GNS or CTY more profitable?

City of London has a net margin of 97.40% compared to Genus' net margin of 7.07%. City of London's return on equity of 22.92% beat Genus' return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% City of London 97.40% 22.92% 4.00%

Which has stronger valuation & earnings, GNS or SMWH?

WH Smith has higher revenue and earnings than Genus. WH Smith is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.17 £7.87M £71.00 30.90 WH Smith £1.59B 0.41 £63.01M -£96.70 N/A

Is GNS or SMWH more profitable?

Genus has a net margin of 7.07% compared to WH Smith's net margin of -9.48%. Genus' return on equity of 9.70% beat WH Smith's return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% WH Smith -9.48% -90.46% 6.62%

Genus (GNS) Competitors

GBX 2,194 -50.00 (-2.23%)

As of 07/31/2026 12:33 PM Eastern

Compare

GNS vs. IGG, DPH, HWDN, CTY, and SMWH

Should you buy Genus stock or one of its competitors? MarketBeat compares Genus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genus include IG Group (IGG), Dechra Pharmaceuticals (DPH), Howden Joinery Group (HWDN), City of London (CTY), and WH Smith (SMWH).

How does Genus compare to IG Group?

Genus (LON:GNS) and IG Group (LON:IGG) are both consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. IG Group pays an annual dividend of GBX 46.50 per share and has a dividend yield of 3.2%. Genus pays out 45.1% of its earnings in the form of a dividend. IG Group pays out 44.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. IG Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, IG Group had 13 more articles in the media than Genus. MarketBeat recorded 13 mentions for IG Group and 0 mentions for Genus. IG Group's average media sentiment score of 0.41 beat Genus' score of 0.00 indicating that IG Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Genus	Neutral
IG Group	Neutral

IG Group has a net margin of 43.07% compared to Genus' net margin of 7.07%. IG Group's return on equity of 26.63% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
IG Group	43.07%	26.63%	10.37%

IG Group has higher revenue and earnings than Genus. IG Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.17	£7.87M	£71.00	30.90
IG Group	£949.10M	5.08	£533.35M	£105.10	13.89

Genus has a beta of 0.901, meaning that its stock price is 10% less volatile than the broader market. Comparatively, IG Group has a beta of 0.531, meaning that its stock price is 47% less volatile than the broader market.

Genus presently has a consensus price target of GBX 3,216.67, indicating a potential upside of 46.61%. IG Group has a consensus price target of GBX 1,338, indicating a potential downside of 8.36%. Given Genus' higher probable upside, equities analysts clearly believe Genus is more favorable than IG Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
IG Group	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

52.2% of Genus shares are owned by institutional investors. Comparatively, 74.0% of IG Group shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 1.2% of IG Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

IG Group beats Genus on 14 of the 17 factors compared between the two stocks.

How does Genus compare to Dechra Pharmaceuticals?

Genus (LON:GNS) and Dechra Pharmaceuticals (LON:DPH) are related companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Genus has a beta of 0.901, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Genus presently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 46.61%. Given Genus' stronger consensus rating and higher probable upside, research analysts clearly believe Genus is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Genus has higher earnings, but lower revenue than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.17	£7.87M	£71.00	30.90
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

In the previous week, Genus' average media sentiment score of 0.00 equaled Dechra Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genus	Neutral
Dechra Pharmaceuticals	Neutral

Genus has a net margin of 7.07% compared to Dechra Pharmaceuticals' net margin of -3.66%. Genus' return on equity of 9.70% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Genus pays out 45.1% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

52.2% of Genus shares are held by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are held by institutional investors. 0.7% of Genus shares are held by company insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Genus beats Dechra Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Genus compare to Howden Joinery Group?

Howden Joinery Group (LON:HWDN) and Genus (LON:GNS) are both consumer discretionary companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Howden Joinery Group pays an annual dividend of GBX 21.30 per share and has a dividend yield of 2.7%. Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. Howden Joinery Group pays out 43.5% of its earnings in the form of a dividend. Genus pays out 45.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Howden Joinery Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Howden Joinery Group had 3 more articles in the media than Genus. MarketBeat recorded 3 mentions for Howden Joinery Group and 0 mentions for Genus. Genus' average media sentiment score of 0.00 beat Howden Joinery Group's score of -0.58 indicating that Genus is being referred to more favorably in the news media.

Company	Overall Sentiment
Howden Joinery Group	Negative
Genus	Neutral

Howden Joinery Group currently has a consensus price target of GBX 1,009.40, suggesting a potential upside of 28.02%. Genus has a consensus price target of GBX 3,216.67, suggesting a potential upside of 46.61%. Given Genus' stronger consensus rating and higher probable upside, analysts clearly believe Genus is more favorable than Howden Joinery Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Howden Joinery Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Howden Joinery Group has a beta of 1.302, indicating that its share price is 30% more volatile than the broader market. Comparatively, Genus has a beta of 0.901, indicating that its share price is 10% less volatile than the broader market.

67.4% of Howden Joinery Group shares are held by institutional investors. Comparatively, 52.2% of Genus shares are held by institutional investors. 1.0% of Howden Joinery Group shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Howden Joinery Group has a net margin of 10.86% compared to Genus' net margin of 7.07%. Howden Joinery Group's return on equity of 22.80% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Howden Joinery Group	10.86%	22.80%	10.70%
Genus	7.07%	9.70%	3.31%

Howden Joinery Group has higher revenue and earnings than Genus. Howden Joinery Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Howden Joinery Group	£2.45B	1.77	£253.42M	£49.00	16.09
Genus	£672M	2.17	£7.87M	£71.00	30.90

Summary

Howden Joinery Group beats Genus on 11 of the 18 factors compared between the two stocks.

How does Genus compare to City of London?

Genus (LON:GNS) and City of London (LON:CTY) are related companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Genus currently has a consensus target price of GBX 3,216.67, indicating a potential upside of 46.61%. Given Genus' stronger consensus rating and higher possible upside, equities analysts clearly believe Genus is more favorable than City of London.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
City of London	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

City of London has lower revenue, but higher earnings than Genus. City of London is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.17	£7.87M	£71.00	30.90
City of London	£568.96M	5.37	£294.08M	£113.99	5.20

Genus has a beta of 0.901, meaning that its stock price is 10% less volatile than the broader market. Comparatively, City of London has a beta of 0.502, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, City of London had 1 more articles in the media than Genus. MarketBeat recorded 1 mentions for City of London and 0 mentions for Genus. City of London's average media sentiment score of 0.64 beat Genus' score of 0.00 indicating that City of London is being referred to more favorably in the news media.

Company	Overall Sentiment
Genus	Neutral
City of London	Positive

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. City of London pays an annual dividend of GBX 21.45 per share and has a dividend yield of 3.6%. Genus pays out 45.1% of its earnings in the form of a dividend. City of London pays out 18.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. City of London is clearly the better dividend stock, given its higher yield and lower payout ratio.

52.2% of Genus shares are owned by institutional investors. Comparatively, 8.7% of City of London shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 0.1% of City of London shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

City of London has a net margin of 97.40% compared to Genus' net margin of 7.07%. City of London's return on equity of 22.92% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
City of London	97.40%	22.92%	4.00%

Summary

City of London beats Genus on 10 of the 18 factors compared between the two stocks.

How does Genus compare to WH Smith?

Genus (LON:GNS) and WH Smith (LON:SMWH) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. WH Smith pays an annual dividend of GBX 17.30 per share and has a dividend yield of 4.0%. Genus pays out 45.1% of its earnings in the form of a dividend. WH Smith pays out -17.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. WH Smith is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Genus' average media sentiment score of 0.00 equaled WH Smith'saverage media sentiment score.

Company	Overall Sentiment
Genus	Neutral
WH Smith	Neutral

52.2% of Genus shares are owned by institutional investors. Comparatively, 71.9% of WH Smith shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 0.9% of WH Smith shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genus presently has a consensus price target of GBX 3,216.67, indicating a potential upside of 46.61%. WH Smith has a consensus price target of GBX 570, indicating a potential upside of 31.52%. Given Genus' stronger consensus rating and higher possible upside, equities analysts clearly believe Genus is more favorable than WH Smith.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
WH Smith	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Genus has a net margin of 7.07% compared to WH Smith's net margin of -9.48%. Genus' return on equity of 9.70% beat WH Smith's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
WH Smith	-9.48%	-90.46%	6.62%

Genus has a beta of 0.901, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, WH Smith has a beta of 0.922, suggesting that its stock price is 8% less volatile than the broader market.

WH Smith has higher revenue and earnings than Genus. WH Smith is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.17	£7.87M	£71.00	30.90
WH Smith	£1.59B	0.41	£63.01M	-£96.70	N/A

Summary

WH Smith beats Genus on 8 of the 15 factors compared between the two stocks.

Get Genus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNS vs. The Competition

Export

Metric	Genus	Diversified Consumer Services Industry	Consumer Discretionary Sector	LON Exchange
Market Cap	£1.48B	£4.87B	£13.19B	£2.79B
Dividend Yield	1.48%	2.82%	53.33%	6.15%
P/E Ratio	30.90	12.89	47.01	368.29
Price / Sales	2.17	20.23	90.65	83,501.30
Price / Cash	50.56	14.73	18.93	27.89
Price / Book	2.65	3.49	4.50	7.04
Net Income	£7.87M	£239.18M	£444.15M	£5.89B
7 Day Performance	-1.17%	0.50%	1.42%	6.05%
1 Month Performance	-4.19%	-2.30%	0.40%	-0.22%
1 Year Performance	-11.89%	5.92%	3.20%	63.72%

Genus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNS Genus	3.3268 of 5 stars	GBX 2,194 -2.2%	GBX 3,216.67 +46.6%	-11.9%	£1.48B	£672M	30.90	480	News Coverage
IGG IG Group	2.0657 of 5 stars	GBX 1,704 +0.4%	GBX 1,288 -24.4%	+29.6%	£5.63B	£949.10M	16.21	2,754	Trending News Earnings Report Analyst Forecast
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HWDN Howden Joinery Group	3.716 of 5 stars	GBX 788.50 +0.1%	GBX 1,009.40 +28.0%	-8.5%	£4.34B	£2.45B	16.09	12,000
CTY City of London	N/A	GBX 591.78 +0.1%	N/A	+19.9%	£3.05B	£568.96M	5.19	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GNS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genus (GNS) Competitors

GNS vs. IGG, DPH, HWDN, CTY, and SMWH

How does Genus compare to IG Group?

Summary

How does Genus compare to Dechra Pharmaceuticals?

Summary

How does Genus compare to Howden Joinery Group?

Summary

How does Genus compare to City of London?

Summary

How does Genus compare to WH Smith?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genus (GNS) Competitors

GNS vs. IGG, DPH, HWDN, CTY, and SMWH

How does Genus compare to IG Group?

Is GNS or IGG a better dividend stock?

Does the media refer more to GNS or IGG?

Is GNS or IGG more profitable?

Which has higher earnings and valuation, GNS or IGG?

Which has more risk and volatility, GNS or IGG?

Do analysts recommend GNS or IGG?

Do insiders and institutionals hold more shares of GNS or IGG?

Summary

How does Genus compare to Dechra Pharmaceuticals?

Which has more risk & volatility, GNS or DPH?

Do analysts prefer GNS or DPH?

Which has stronger valuation & earnings, GNS or DPH?

Does the media refer more to GNS or DPH?

Is GNS or DPH more profitable?

Is GNS or DPH a better dividend stock?

Do institutionals & insiders have more ownership in GNS or DPH?

Summary

How does Genus compare to Howden Joinery Group?

Is HWDN or GNS a better dividend stock?

Does the media prefer HWDN or GNS?

Do analysts prefer HWDN or GNS?

Which has more risk & volatility, HWDN or GNS?

Do insiders & institutionals have more ownership in HWDN or GNS?

Is HWDN or GNS more profitable?

Which has better valuation & earnings, HWDN or GNS?

Summary

How does Genus compare to City of London?

Do analysts recommend GNS or CTY?

Which has higher earnings and valuation, GNS or CTY?

Which has more volatility & risk, GNS or CTY?

Does the media prefer GNS or CTY?

Is GNS or CTY a better dividend stock?

Do institutionals & insiders have more ownership in GNS or CTY?

Is GNS or CTY more profitable?

Summary

How does Genus compare to WH Smith?

Is GNS or SMWH a better dividend stock?

Does the media refer more to GNS or SMWH?

Do institutionals and insiders hold more shares of GNS or SMWH?

Do analysts rate GNS or SMWH?

Is GNS or SMWH more profitable?

Which has more risk & volatility, GNS or SMWH?

Which has stronger valuation & earnings, GNS or SMWH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools